OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced today that it has been selected by Amarex, a Mid-Atlantic based Contract Research Organization (CRO) to provide eClinical solutions for an upcoming Phase III trial investigating the use of a medical device for wound healing.
The study will be conducted at over 30 sites and will recruit up to 300 patients over the course of two years. Amarex also joins OmniComm's CRO Preferred Program, which will allow them to offer OmniComm's flexible, robust electronic data capture solution, TrialMaster(TM), to their clients. Amarex also benefits from the CRO Program's distinct advantages that include fixed pricing with no hidden fees, complete sales and marketing support, and dedicated hosting services in OmniComm's world class hosting facility.
"We are honored that such a well-reputed CRO like Amarex has joined our CRO Preferred Program and look forward to working closely with them on this high profile study," remarked Stephen Johnson, COO of OmniComm Systems. "Amarex has a reputation for delivering superior service to their customers - a commitment that we share here at OmniComm. The combination of our products and services will be beneficial for both companies, but more importantly will offer our customers the solutions they need to bring life saving drugs and devices to market."
Garlic’s antioxidant and nitric oxide boosting effects may help lower blood pressure